Leica Stellaris 8 Confocal Microscope
Leica Stellaris 8 共焦显微镜
基本信息
- 批准号:10431426
- 负责人:
- 金额:$ 65.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Conventional confocal microscopy is a powerful tool for special-temporal cellular and tissue
imaging, typically with up to four fluorophores. Recently, there has been an increasing demand
for multiplex, high-resolution analysis. However, with most currently available microscopes it is
technically impossible to detect fluorophores in the near-infrared (NIR) range, thus limiting the
multiplexing capability. The enhanced detection is required not only for detection in the near-
infrared (NIR), but also because this allows the use of directly conjugated antibodies when the
choice of species in which any primary antibodies were generated is limited. Establishing a user-
friendly multiplex imaging system to complement genome-wide, next-generation sequencing
analysis is an unmet need. An additional limitation of conventional confocal microscopy is its
resolution. Several recently developed confocal scanning microscopes are beginning to meet this
need by combining superior detectors and advanced computational deconvolution to enhance
both multiplexing options and resolution. Both multiplexing capability and resolution are
particularly imperative for the major users on this proposal who focus on developmental and stem
cell biology to deepen our understanding of human disease and develop innovative treatments.
We therefore propose to acquire a Leica Stellaris 8 microscope that allows multiplexing by
providing excitation and enhanced detection in the NIR, as well as computational super-
resolution.
传统的共聚焦显微镜是一种强有力的工具,用于特殊时间的细胞和组织
成像,通常使用多达四个荧光团。最近,
用于多重高分辨率分析。然而,对于目前大多数可用的显微镜,
技术上不可能检测近红外(NIR)范围内的荧光团,因此限制了
多路复用能力增强的检测不仅需要用于近距离检测,
这不仅是因为这允许使用近红外(NIR),而且还因为这允许在使用直接缀合的抗体时使用直接缀合的抗体。
产生任何一抗的物种的选择是有限的。建立用户-
友好的多重成像系统,以补充全基因组,下一代测序
分析是一个未满足的需求。常规共焦显微镜的另一个限制是其
分辨率最近开发的几种共焦扫描显微镜开始满足这一点
需要通过结合上级检测器和先进的计算反卷积来增强
多路复用选项和分辨率。多路复用能力和分辨率均
对于关注发展和科学、技术、工程和管理的主要用户来说,
细胞生物学,以加深我们对人类疾病的理解,并开发创新的治疗方法。
因此,我们建议购买一台Leica Stellaris 8显微镜,可以通过以下方式进行多路复用
提供激发和增强的近红外检测,以及计算超级,
分辨率
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HANS-WILLEM E SNOECK其他文献
HANS-WILLEM E SNOECK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HANS-WILLEM E SNOECK', 18)}}的其他基金
Lung epithelial cell specification in human pluripotent stem cells
人多能干细胞的肺上皮细胞规格
- 批准号:
10378129 - 财政年份:2019
- 资助金额:
$ 65.16万 - 项目类别:
Lung epithelial cell specification in human pluripotent stem cells
人多能干细胞的肺上皮细胞规格
- 批准号:
9902521 - 财政年份:2019
- 资助金额:
$ 65.16万 - 项目类别:
Mitochondrial Maintenance Mechanisms of Stem Cells and Aging
干细胞的线粒体维持机制与衰老
- 批准号:
9751137 - 财政年份:2017
- 资助金额:
$ 65.16万 - 项目类别:
Mitochondrial Regulation of Hematopoietic Stem Cells
造血干细胞的线粒体调节
- 批准号:
10551891 - 财政年份:2017
- 资助金额:
$ 65.16万 - 项目类别:
Mitochondrial Maintenance Mechanisms of Stem Cells and Aging
干细胞的线粒体维持机制与衰老
- 批准号:
10192621 - 财政年份:2017
- 资助金额:
$ 65.16万 - 项目类别:
Mitochondrial Regulation of Hematopoietic Stem Cells
造血干细胞的线粒体调节
- 批准号:
10375950 - 财政年份:2017
- 资助金额:
$ 65.16万 - 项目类别:
Mitochondrial regulation of hematopoietic stem cells
造血干细胞的线粒体调控
- 批准号:
9218717 - 财政年份:2017
- 资助金额:
$ 65.16万 - 项目类别:
Modeling, pathogenesis and treatment of idiopathic pulmonary fibrosis
特发性肺纤维化的建模、发病机制和治疗
- 批准号:
9516638 - 财政年份:2016
- 资助金额:
$ 65.16万 - 项目类别:
Modeling, pathogenesis and treatment of idiopathic pulmonary fibrosis
特发性肺纤维化的建模、发病机制和治疗
- 批准号:
9509525 - 财政年份:2016
- 资助金额:
$ 65.16万 - 项目类别:
Modeling, pathogenesis and treatment of idiopathic pulmonary fibrosis
特发性肺纤维化的建模、发病机制和治疗
- 批准号:
10192798 - 财政年份:2016
- 资助金额:
$ 65.16万 - 项目类别:
相似国自然基金
Complement C6蛋白抑制DNA损伤修复增敏甲状腺乳头状癌放射性碘治疗的作用及其机制
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Investigating the role of complement component 5a in ANCA-associated vasculitis
研究补体成分 5a 在 ANCA 相关血管炎中的作用
- 批准号:
MR/Y000854/1 - 财政年份:2024
- 资助金额:
$ 65.16万 - 项目类别:
Fellowship
Anti-Complement Immunotherapy for Pancreatic Cancer
胰腺癌的抗补体免疫治疗
- 批准号:
10751872 - 财政年份:2024
- 资助金额:
$ 65.16万 - 项目类别:
NSF Convergence Accelerator, Track M: TANDEM: Tensegrity-based Assistive aND rehabilitation Exosuits to complement human bioMechanics
NSF 融合加速器,轨道 M:TANDEM:基于张拉整体的辅助和康复外装,以补充人体生物力学
- 批准号:
2344385 - 财政年份:2024
- 资助金额:
$ 65.16万 - 项目类别:
Standard Grant
Development of a novel oral vaccine for fish: Synergy of chitosan nano particle and complement-mediated opsonization
新型鱼类口服疫苗的开发:壳聚糖纳米颗粒与补体介导的调理作用的协同作用
- 批准号:
24K17960 - 财政年份:2024
- 资助金额:
$ 65.16万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Crosstalk between purinergic signaling and the complement system in sepsis-induced immunosuppression.
脓毒症引起的免疫抑制中嘌呤能信号传导与补体系统之间的串扰。
- 批准号:
23H03013 - 财政年份:2023
- 资助金额:
$ 65.16万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Complement Protein C1q Regulation of Macrophage Metabolic Pathways
补体蛋白 C1q 对巨噬细胞代谢途径的调节
- 批准号:
10629550 - 财政年份:2023
- 资助金额:
$ 65.16万 - 项目类别:
Defining the impact of complement inhibition by tick saliva in tick-borne virus evolution and adaptive immune responses in murine models of infection
定义蜱唾液抑制补体对蜱传病毒进化和小鼠感染模型适应性免疫反应的影响
- 批准号:
10535945 - 财政年份:2023
- 资助金额:
$ 65.16万 - 项目类别:
Complement Resistance Acquired During Acute to Persistent Rubulavirus Infection
急性至持续性风疹病毒感染期间获得的补体耐药性
- 批准号:
10645486 - 财政年份:2023
- 资助金额:
$ 65.16万 - 项目类别:
Inhibition of Complement Pathways with VCP As A Treatment For Alzheimer's Disease
VCP 抑制补体途径治疗阿尔茨海默病
- 批准号:
10602757 - 财政年份:2023
- 资助金额:
$ 65.16万 - 项目类别:














{{item.name}}会员




